DioGenX is a pioneering biotech brand that specializes in the regeneration of insulin-producing beta cells to treat diabetes. Established in 2020, the company is at the forefront of developing cutting-edge recombinant proteins to address type 1 diabetes (T1D). Their lead program focuses on leveraging the Wnt/β-catenin signaling pathway to regenerate pancreatic beta cells, providing a transformative disease-modifying therapy for T1D.

Although currently in preclinical development, DioGenX is propelled by a network of renowned diabetes experts and an impressive consortium of investors that includes industry leaders like Boehringer Ingelheim Venture Fund, Roche Venture Fund, Eli Lilly and Company, and JDRF T1D Fund. With its headquarters in Marseille, France, and research labs in Nice, DioGenX aims to revolutionize diabetes treatment and improve the lives of millions of patients worldwide